Skip to main content
Figure 5 | Experimental Hematology & Oncology

Figure 5

From: Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies

Figure 5

Detailed analysis of CD20 expression in residual tumor cells following treatment of animals with rituximab. A1 – Isotype control for CD 20; A2 – Isotype control for anti-rituximab (anti-C2B8); B1– CD 20, untreated animal (positive expression); B2 – Anti-C2B8, untreated animal (negative expression); C1– CD 20, RTX-treated animal (negative expression); C2 – Anti-C2B8 in RTX-treated animal (positive expression).

Back to article page